Development and Preclinical Evaluation of a CPAP-Compatible EtCO2 Sampler

Sahil Sethi[1,2,*], Gene Hobbs[2], Devin Hubbard[2], Kenneth Donnelly[2], Joseph M. Grover[3], Imran

Rizvi[2,4, *]

[1]Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA

[2]Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill,

Chapel Hill, NC, North Carolina State University, Raleigh, NC 27599, USA

[3]Department of Emergency Medicine, University of North Carolina, Chapel Hill, NC 27514, USA

[4]Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at

Chapel Hill, Chapel Hill, NC 27599, USA

11
*Corresponding authors

Emails:

sethis@uchicago.edu (SS)

imran.rizvi@unc.edu (IR)

Author Contributions

S.S. formed the idea, conducted the literature search, and designed the study; G.H., D.H, K.D.,

J.G., and I.R. provided technical feedback; S.S. and G.H. collected data; S.S. and I.R. prepared

the manuscript; all authors reviewed, edited, and approved the manuscript.

Declaration of Interests

The authors declare no competing interests.

Abstract

BACKGROUND: Capnography is a vital tool in EMS because changes to end-tidal CO_2 ($ETCO_2$) generally precede blood oxygen desaturation, and waveform morphology can be used to assess bronchial patency. Many of capnography's indications overlap with those of continuous positive airway pressure (CPAP) therapy. However, there is currently no validated method to measure capnography during CPAP administration, and combining the two technologies in the prehospital setting lacks investigation in peer-reviewed literature.

METHODS: We developed a novel exhalatory CO_2 sampler designed to seamlessly integrate with existing prehospital CPAP systems, manufactured via stereolithography. Using a Human Patient Simulator, we compared this novel sampler *in vitro* with a traditional nasal-oral cannula (NC), examining the effects of CPAP administration on $ETCO_2$, capnogram shape, and respiration rate (RR).

RESULTS: The CCA maintained an air-tight seal during CPAP administration and showed no significant differences in $ETCO_2$ values or RR compared to the NC. However, CPAP administration significantly reduced $ETCO_2$ values and altered capnogram morphology for both samplers. These changes indicate that CPAP itself affects capnography readings, necessitating caution in interpreting these measurements.

CONCLUSIONS: The novel CCA is a viable tool for integrating capnography with CPAP in prehospital settings, but the effects of CPAP on capnography readings must be further studied. Future research should focus on clinical trials with human subjects to validate these findings and improve the interpretation of capnography data during CPAP therapy.

Key Words: End-tidal carbon dioxide, capnography, capnometry, oxygen therapy, noninvasive ventilation, continuous positive airway pressure, prehospital, emergency medical services

Abstract

Introduction

Materials and Methods

CPAP-Capnography Adapter (CCA) Design Process & Manufacturing

Materials

Human Patient Simulator

Experimental Design

Statistical Analysis

Results

Development of CPAP-Capnography Adapter

Effects on Capnography Waveform

Effects on End-Tidal CO2

Effects on Respiration Rate

Discussion

Development of CPAP-Capnography Adapter

Effects on Capnography Waveform

Capnography Sampler Effect on ETCO2 and Respiration Rate

Mask Condition Effect on ETCO2 and Respiration Rate

Relationship with Previous Studies

Limitations

Conclusions

Acknowledgments

References

Supporting Information

Abbreviations:

EMS - Emergency Medical Services

CO_2 - Carbon Dioxide

CPAP - Continuous Positive Airway Pressure

$ETCO_2$ - End-Tidal Carbon Dioxide (mmHg)

$PaCO_2$ - Partial Pressure of Arterial Carbon Dioxide (mmHg)

SpO_2 - Blood Oxygen Saturation

RR - Respiration Rate (breaths/min)

NC - Nasal-Oral Cannula

CCA - CPAP-Capnography Adapter

MAP - Mean Arterial Pressure

HPS - Human Patient Simulator

PEEP - Positive End Expiratory Pressure

Introduction

Respiratory issues are among the most common causes of 911 calls in the United
States (1). Once on scene, EMS personnel interview the patient and use vital signs—such as
heart rate, blood pressure, respiration rate (RR), pulse oximetry, and capnography—in addition
to their physical exam findings to determine possible causes for their breathing difficulties.
Capnography is particularly beneficial as it can typically detect changes to a patient's breathing
before pulse oximetry (2–4). For example, one study found that, for acute respiratory events,
abnormal $ETCO_2$ results were observed before SpO_2 changes or observed hypoventilation in
70% of cases (2). Pulse oximetry is also known to overestimate oxygen saturation in patients
with darker skin (5–7). Capnography's physiological relevance stems from its correlation with
$PaCO_2$, which regulates the respiratory drive. Directly measuring $PaCO_2$ requires an
interventional test that is not practical in the prehospital setting, such as arterial blood gas
analysis (8). There is some debate surrounding the correlation of $ETCO_2$ to $PaCO_2$, but several
studies have found good correlation in healthy patients and patients with compromised
pulmonary function who are spontaneously breathing (9–12). Capnography has been shown to
be a valuable screening tool for mortality predictions in patients with sepsis (13,14). Also, in
penetrating trauma patients, capnography measurements correlate with serum lactate levels (an
indicator of tissue hypoxia and shock) and can predict the odds of the patient requiring operative
intervention (15). See **Fig. 1B & 1D** for example capnograms.

106   [Figure 1]

Figure 1. Capnography and Continuous Positive Airway Pressure (CPAP). (A) Nasal cannula (NC)
commonly used for prehospital sidestream capnography sampling. (B) Example capnogram for a healthy
individual (i) and an individual with bronchospasm (ii); peaks indicate exhalations while troughs indicate
inhalations, and the end of the exhalatory plateau yields the $PETCO_2$ measurement (labeled with a star).
For the first waveform, phases I-IV are labeled, along with □- and □-angles. (C) Common prehospital

CPAP setup with NC placed below the mask for capnography sampling; CO_2 gas line is circled in purple.

(D) Example EMS monitor depicting a capnography waveform; CO_2 gas line insertion is circled in purple;

standard orange capnography port (not shown) is used for insertion.

Prehospital capnography is most commonly used for validating endotracheal tube

placement (16), as well as helping identify asthma, chronic obstructive pulmonary disease

(COPD), pulmonary embolism (PE), and congestive heart failure (CHF) (17–19). The

morphology of the capnogram is crucial for assessing bronchial patency as bronchospasm

tends to yield a "shark fin" waveform (prolonged phase II with increase or loss of □-angle)

(20,21), which is depicted in **Fig 1B.ii**. Monitoring of the waveform is currently used to assess

response to bronchodilators (20,22). Prehospital indications for CPAP strongly align with those

of capnography and include CHF, COPD, asthma, acute bronchitis, pneumonia, and near-

drownings with signs of pulmonary edema (23,24). Prehospital CPAP has been shown to

improve patient outcomes by reducing the need for intubation (and thus decreasing the

likelihood of developing ventilator-associated pneumonia) (25), improving vital signs, and

reducing myocardial damage—its use is also associated with reduced mortality (24,26). Using

capnography to monitor the effectiveness of CPAP would allow for the rapid determination of

ineffective therapy and a quick decision to be made regarding switching to an invasive option

(27,28). This would also align with the 2011 AARC Clinical Practice Guideline on capnography,

which recommends its use for monitoring response to therapies that improve the ventilation-

perfusion (V/Q) ratio (23).

Despite these points, the two technologies are not currently easily compatible. Common

EMS cardiac monitors with built-in sidestream capnography sensors, such as the Physio-

Control LIFEPAK-15, are used with a nasal-oral cannula (NC) sampler for spontaneously

breathing patients, and an in-line sampler for intubated patients (27,29). Non-invasive ventilation

(NIV) dilutes exhalations, so sampling as close to the nares/mouth as possible is best (27).

Thus, using an NC sampler is generally preferred during NIV (30). However, placing a cannula
beneath a CPAP mask is not ideal as it allows gas to escape at the location where the sampling
line exits the mask (27); significant leaks are problematic as they decrease CO_2 elimination and
$ETCO_2$ values (30). Despite this, due to anecdotal evidence, some EMS education sources
recommend using the NC sampler for capnography during CPAP (31–33), and EMS systems
have already added this recommendation to their protocols (34).

In this study, we aim to design and manufacture a novel exhalatory CO_2 sampler,
referred to as the CPAP-Capnography Adapter (CCA), that will be compatible with existing
prehospital CPAP devices. The CCA will be developed to maintain the system's airflow while
ensuring compatibility with existing EMS cardiac monitors that feature capnography monitoring
capabilities. To assess the performance of this novel device, we will conduct preliminary *in vitro*
testing using a Human Patient Simulator (HPS). This testing will compare the CCA to the
traditional nasal-oral cannula (NC) to evaluate the impact of CPAP administration on ETCO2
measurements, capnogram morphology, and respiratory rate (RR).

Materials and Methods

CPAP-Capnography Adapter (CCA) Design Process &
Manufacturing

A novel method for measuring capnography during CPAP was invented and tested
alongside the nasal-oral cannula method. Engineering sketches are provided in **Fig. 2**. The new
method involved attaching an elbow-shaped adapter to a prehospital CPAP setup between the
mask and flow regulator. To ensure an air-tight seal, flat ring seals were created out of duct tape
and applied to each end of the elbow (functioning similarly to square profile O-rings). A nasal
sampling element was fed through this adapter and into the mask, allowing for sidestream

capnography sampling. To prevent the nasal sampler's tubing from getting crimped by the

elbow as it passed into it, a short internal guide tube was added to provide greater support. The

nasal sampler base slid onto existing CapnoLine® tubing containing a standard orange

capnography plug; the sampler fit snugly via friction but was further secured via duct tape.

Combined, this setup is referred to as the CPAP-Capnography Adapter (CCA).

[Figure 2]

Figure 2. Design sketches for novel CPAP-capnography adapter (CCA) system. Orthographic and

isometric views are depicted for both the elbow adapter (top) and nasal sampler (bottom). All dimensions

are in millimeters, and angles are in degrees. These sketches represent the conceptual design of the

CCA.

The CCA elbow and nasal sampler were designed using OnShape Computer-Aided

Design (CAD) software and printed with a Formlabs Form 2 stereolithography (SLA) 3D printer

(see **Fig. 3A**). Formlabs Clear V4 resin was selected as the elbow material due to its

translucency and rigidity (35). Formlabs Elastic 50A resin was selected as the nasal sampler

material due to its translucency and flexibility (36), the latter property allowing for the

accommodation of various nose sizes. After printing, an isopropyl alcohol (IPA) bath was used

to vigorously wash parts for 15 minutes. Then, an IPA-filled syringe was used to clear excess

resin from small channels, and the parts were soaked in a clean IPA bath for an additional 15

minutes. Next, an ultraviolet (UV) light & heat cure was conducted according to the

manufacturer's guidelines (power density: 1.25 mW/cm^2; LED centered at 405 nm; 60 °C for 20

minutes for Elastic 50A and 60 minutes for Clear V4) (35–37).

[Figure 3]

Figure 3. CPAP-Capnography Adapter (CCA) manufacturing & experimental setup. (A) The CCA

being manufactured using the stereolithography 3D printing process. (B) A labeled diagram of the final

CCA design. (C) Integration of the CCA into a prehospital CPAP setup. (D) A display from the Human

Patient Simulator (HPS) showing modeled $ETCO_2$ & respiration rate. (E) CCA applied to the HPS without a CPAP mask. (F) CCA integrated into a prehospital CPAP setup and applied to the HPS.

Materials

A stock CPAP kit containing a Pulmodyne O_2-MAX™ and Curaplex O_2 Max Trio BiTrac ED Mask was used. For all experimental groups, CPAP tubing was fully contracted to standardize dead space, and the PEEP valve was set to 10 cm H_2O. The following nasal-oral cannula was used: Covidien Smart CapnoLine® Plus O_2, Adult/Intermediate CO_2 Oral/Nasal Sampling Set with O_2 Tubing. For their respective trials, the CCA and NC were plugged into the capnography port on a Physio-Control LIFEPAK-15 monitor to obtain capnograms and $ETCO_2$ values. As the HPS is meant to accurately model a variety of respiratory parameters, $ETCO_2$ and respiration rate could not be directly manipulated to test the full range of expected values for each because this could result in a biologically inaccurate combination of parameters. Therefore, pre-programmed patient respiratory profiles were used for testing. For each experimental group, the HPS was kept in the supine position, and CCA and NC positioning were kept constant.

Human Patient Simulator

The CAE Human Patient Simulator (HPS) is a high-fidelity medical training tool designed to replicate human physiological responses, with a particular emphasis on modeling respiratory functions. It features realistic chest rise and fall, variable lung compliance and resistance, and the ability to simulate spontaneous breathing, apnea, and mechanical ventilation scenarios. Vital signs can be measured on it with traditional tools, as it exhales oxygen and inhales carbon dioxide; blood pressure can also be manually auscultated (38). These capabilities make it an incredibly useful tool for preclinical testing of novel medical devices, such as in this study. Even

for low-risk devices such as the CCA, such preclinical testing is essential to determine if the new

device warrants the time and cost of conducting human trials.

Experimental Design

The following six configurations were tested: (1) NC with no CPAP mask nor O_2 flowing,

(2) CCA with no CPAP mask nor O_2 flowing, (3) NC with CPAP mask but no O_2 flowing, (4) CCA

with CPAP mask but no O_2 flowing, (5) NC with CPAP mask and O_2 flowing, and (6) CCA with

CPAP mask and O_2 flowing. Groups 1 and 2 are controls for evaluating the effects of CPAP

mask dead space (Groups 3 & 4) and CPAP therapy (Groups 5 & 6) on capnography sampled

via NC and CCA, respectively. In groups 3 and 4, the CPAP mask was applied, but the tubing

was not connected to an oxygen source and remained open to ambient air, allowing the

mannequin to breathe room air. This setup was included to assess the effect of added

anatomic/mechanical dead space from the CPAP mask and tubing on capnography

measurements, as previous studies have shown that simply applying a mask can increase

$ETCO_2$ (39). These groups served as positive controls, validating that our setup can detect the

changes in $ETCO_2$ that have been observed in other studies, thereby allowing us to better

contextualize the results from the other experimental groups where CPAP was actively

delivering oxygen. All experimental groups are summarized in **Table 1**.

Table 1. Experimental groups used for testing on Human Patient Simulator (HPS).

	No CPAP mask, no O2 ("no mask")	CPAP mask, no O2 ("mask with no O2")	CPAP mask with O2 ("mask with CPAP")
NC	Group 1	Group 3	Group 5
CCA	Group 2	Group 4	Group 6

234
Groups 1-6 were each tested on three HPS standardized simulated patients: Stan D. Ardman II (Healthy

Adult Male), Grandma Smokey (COPD Patient), & Kenton Parkers (CHF & COPD Patient); these profiles

have set-point $ETCO_2$ values of 33 mmHg, 22 mmHg, and 34 mmHg, respectively.

For groups 1-6, data were obtained from three standardized simulated patients from the

HPS system: Stan D. Ardman II (Healthy Adult Male), Grandma Smokey (COPD Patient), &

Kenton Parkers (CHF & COPD Patient). From their pre-programmed respiratory profiles, their

$ETCO_2$ targets were 33 mmHg, 22 mmHg, and 34 mmHg, respectively. The HPS continuously

adjusts modeled vital signs to remain consistent with this $ETCO_2$, as well as the rest of its pre-

programmed patient profile. As groups 1-6 were tested for all three patients, 18 total trials were

conducted. For each trial, the $ETCO_2$ value and respiration rate were recorded from the

LIFEPAK-15 monitor's screen for 20 consecutive breaths. Software limitations of the LIFEPAK-

15 and HPS prevented the direct export of the data to a spreadsheet. Consequently, videos

were taken of both displays, timestamps were lined up, and values were entered into a

spreadsheet to facilitate data collection. Trials were spaced one minute apart to allow for the

modeled vital signs from the HPS to stabilize in response to changes. Only 20 breaths per

group were measured because the HPS is designed to maintain constant respiratory profiles,

resulting in minimal variation once values have stabilized. Measuring more than 20 breaths

within a single trial would not provide additional variability but could lead to oversampling,

artificially inflating the precision of the data. Additionally, this method aligns with a similar study

that used an ASL-5000 lung simulator to compare various methods of interfacing capnography

with hospital oxygen masks (39). By averaging data across 20 breaths, we reduce the risk of

overfitting while capturing representative data from each trial.

258   Statistical Analysis

For all tests, alpha was chosen to be 0.05. As each simulated patient had a different set-

point $ETCO_2$, measured $ETCO_2$ values at each breath were normalized by dividing by their

respective target $ETCO_2$. Unlike $ETCO_2$, the HPS displayed the true RR value for each breath,

so the true and measured values were used to calculate RR percent error. Values were

averaged across the 20 breaths in each trial to avoid overfitting during analysis.

Normalized $ETCO_2$ and RR percent error were analyzed for any effects caused by the

following nominal independent variables: capnography sampler (NC or CCA), mask condition

(no mask, mask with no O_2, and mask with CPAP), and patient (Stan D. Ardman II, Grandma

Smokey, & Kenton Parkers). In accordance with the current literature (40–42), a mixed effects

model was constructed with "patient" as a random effect. Using the mixed model (multilevel

linear model) feature within JMP Pro 17, the full factorial of capnography sampler, mask

condition, and patient were selected as model effects; all terms containing "patient" were

marked as random effects. The t-statistics were then used to obtain specific p-values. All

statistics were also validated using Python's statsmodels package.

Results

Development of CPAP-Capnography Adapter

The first prototype of the CPAP-Capnography Adapter (CCA) is depicted in **Fig. S1A**. An elbow-shaped design was chosen to allow the CapnoLine® tubing to pass through a hole in the wall of the adapter without needing to bend—which could cut off gas flow (see **Fig. S1B**). To ensure compatibility with existing EMS cardiac monitors and ensure the final CCA is simple and cheap to manufacture, existing CapnoLine® tubing with a standard orange capnography port plug was used. For this prototype, both components were printed with Clear V4 Formlabs resin, allowing them to be manufactured together in a single print.

Despite precisely measuring the dimensions of the existing CPAP setup, the first prototype CCA did not have an air-tight fit with the mask; air could be both felt and heard escaping. Further, the existing CapnoLine® tubing could get easily crimped if the mask was moved around and the tubing not kept perfectly straight. Additionally, despite soaking and vigorously washing the elbow adapter and nasal sampler in isopropyl alcohol (IPA) per Formlabs' guidelines prior to the UV (ultraviolet light) bath, excess resin was found within one of the prongs of the nasal sampler, narrowing its internal diameter on that side. As a result, several changes were implemented for the second prototype.

The second prototype added an internal guide tube to better distribute shear forces on the CapnoLine® tubing, reducing the likelihood of crimping (see **Fig. S1C**). Next, a syringe was filled with IPA and used to flush out the channels within the nasal sampler of any excess resin. Last, flat ring seals were created out of duct tape and applied to each end of the elbow (functioning similarly to square profile O-rings) (see **Fig. 3B-C**).

The adjustments to the second prototype were all successful—the internal guide tube prevented crimping upon movement of the CPAP mask, the nasal sampler was free of excess

resin, and no leaks could be heard or felt upon connecting the CCA to a CPAP mask and turning on the oxygen supply. However, the rigidity of the nasal sampler caused it to snap on several occasions when removing the 3D printing supports and sanding it down. The rigid material might also be uncomfortable to a human patient, so the decision was made to switch to Elastic 50A resin for the nasal sampler only. While this required an additional print, the small size of the nasal sampler ensured that this did not add to the complexity of the manufacturing process.

Three 3D prints of the final design were created to ensure reproducibility (though only one was tested on the HPS to ensure standardization). Supports were auto-generated for each print, causing a slightly different total resin amount from print to print. However, the elbow adapter remained below 40 mL resin per print, and the nasal sampler remained below 5 mL resin per print. Thus, the total cost of the CCA resin remained below $7 (based on current resin prices of $149/L for Clear V4, and $199/L for Elastic 50A) (43). The remaining parts of the setup, such as the CapnoLine® tubing/plug and tape, are commonly found in ambulances that carry monitors with capnography monitoring capabilities.

Effects on Capnography Waveform

For all three patients during the experiment, it was noted that a leak was audible and could be felt by the experimenter's hands around the sides of the CPAP mask for the NC groups when oxygen was administered (Group 5); no such leaks were noticed for the corresponding CCA group (Group 6).

Representative capnography waveforms are depicted in **Fig. S2**. Within each trial, waveform shape remained consistent across the 20 recorded breaths. It was noted that the waveforms obtained via the CCA appeared to consistently show more dead space compared to the NC capnograms, indicated by the waveform not fully returning to 0 mmHg during each

inhalation. This was most noticeable in the "no mask" and "mask with no O_2" conditions. These

same capnograms appeared to have increased □- and □-angles compared to those from the

NC, with bilateral blunting of the waveforms.

Across both the NC and CCA trials, waveform shape remained similar when transitioning

from the "no mask" to the "mask with no O_2" condition, but a small increase in dead space was

noted. Note that the CPAP setup allowed for exhaled gas to escape through a valve near the

PEEP regulator when oxygen was not flowing, reducing CO_2 rebreathing; the high flow rate

during CPAP forces this valve closed to prevent leaks while administering the therapy. The

"mask with CPAP" waveform consistently had a lower magnitude and sharper peak compared to

the "no mask" and "mask with no O_2" conditions. Specifically, the expiratory upstroke (phase II)

appeared relatively unaffected, but the alveolar plateau (phase III) and inspiratory downstroke

(phase IV/0) were severely blunted, with □-angles appearing to be around 180 degrees. These

morphological changes were present when administering CPAP in all three patients. There were

no noticeable consistent differences between NC and CCA waveforms when CPAP was being

administered.

Effects on End-Tidal CO2

Results for "ETCO$_2$ normalized to patient" compared against "capnography sampler" and

"mask condition" are depicted in **Table 2** and **Fig. 4A.** Capnography sampler was not found to

significantly affect normalized ETCO$_2$ (NC: 1.005, CCA: 0.897; p = 0.25). The interaction

between mask condition and capnography sampler was also found to have no significant effect

on normalized ETCO$_2$ (p = 0.69), but mask condition alone did have a significant effect (p =

0.031). Specific model parameter t-statistics revealed that the "mask with CPAP" normalized

ETCO$_2$ was significantly less than that of the "no mask" condition (0.810 vs. 0.983, respectively;

p = 0.015); moreover, the "mask with no O_2" normalized $ETCO_2$ was significantly greater than

that of the "no mask" condition (1.060 vs. 0.983, respectively; p = 0.033).

Table 2. End-tidal CO_2 ($ETCO_2$) normalized to target for all experimental groups.

	Naso-oral Cannula	CPAP-Capnography Adapter	**Total**
No Mask	1.014 (0.033)	0.951 (0.097)	0.983 (0.073)
Mask with No O2	1.094 (0.045)	1.026 (0.134)	1.060 (0.097)
Mask with CPAP	0.905 (0.285)	0.714 (0.118)	0.810 (0.221)
Total	1.005 (0.167)	0.897 (0.174)	0.951 (0.174)

353   Standard deviation is provided for each respective value in parenthesis immediately after it.

354   [Figure 4]

Figure 4. Normalized $ETCO_2$ and RR percent error plotted by mask condition. Horizontal black lines

indicate average values for each mask condition. No significant differences were found between NC

(naso-oral cannula) and CCA (CPAP-capnography adapter) groups, so both are shown together. *

indicates p < 0.05 from the mixed-effects model. Data points reflect the 20-breath average per trial. CPAP

= continuous positive airway pressure, O_2 = oxygen gas.

Effects on Respiration Rate

Respiration rate percent error data based on mask condition and capnography sampler

are depicted in **Table 3** and **Fig. 4B**. Capnography sampler did not significantly affect RR

percent error (NC: 9.423%, CCA: 0.690%; p = 0.40). Mask condition and the interaction

between mask condition and capnography sampler were both found to have no significant effect

on RR percent error (p = 0.37 & 0.44, respectively). One of the 20-breath trials produced a high

average RR percent error for the 'mask with CPAP' and 'NC' conditions (13.677% & 9.423%,

respectively). In the Group 5 (NC; mask with CPAP) condition for the patient 'Kenton Parkers'

(CHF & COPD Patient), an artifact consistently caused the LIFEPAK-15 monitor to double the

measured respiration rate for all 20 breaths. This artifact reflects a potential limitation of the NC

when used with high-flow CPAP. While this artifact increased the mean and variance in the

Group 5 data, removing this trial did not alter the overall results. The statistical analysis showed

no significant differences in RR percent error between mask conditions or capnography

samplers whether the artifact was included or not. Therefore, we retained this trial in the

analysis to highlight a potential limitation of the NC during high-flow CPAP.

Table 3. Respiration rate (RR) percent error for all experimental groups.

	Naso-oral Cannula	CPAP-Capnography Adapter	**Total**
No Mask	1.718 (2.672)	0.192 (0.333)	0.955 (1.897)
Mask with No O2	0.584 (0.301)	0.491 (0.851)	0.537 (0.573)
Mask with CPAP	25.969 (41.468)	1.385 (0.147)	13.677 (29.482)
Total	9.423 (24.206)	0.690 (0.709)	5.056 (17.209)

379   Standard deviation is provided for each respective value in parenthesis immediately after it.

Discussion

Development of CPAP-Capnography Adapter

The final design of the CCA met its design objectives: it is compatible with existing EMS

cardiac monitors (tested via the LIFEPAK-15) and does not cause any identifiable leaks during

CPAP administration. Further, the low cost of manufacturing ensures that expense would not be

a significant barrier to the adoption of the device in the clinical setting. However, data from

human subjects would be necessary prior to such adoption, which is outside the scope of this

study. Initial preclinical evaluation, as conducted here, is essential to determine if the device

warrants the time, resources, and ethical considerations of conducting human studies. High-

fidelity models such as the HPS used here are useful tools for such preclinical evaluation.

Effects on Capnography Waveform

The main difference between the NC and CCA waveforms was the observed increase in

dead space—indicated by the capnogram not returning to baseline during inhalation—and

altered morphology when using the CCA. This likely resulted from CO_2 accumulating in the

sampling line, though it did not trend upward, indicating that exhalations were able to escape to

some extent. The increased CO_2 within the mask observed here is consistent with increased

mechanical/anatomic dead space—a known factor when using any breathing apparatus that

introduces additional space between the patient's airway and the point of exhalation (44). While

the increase in dead space is consistent with previous studies, such as Phillips et al. (2017)

(39), further testing is needed to confirm which component of the CCA's design caused this

artifact. Specifically, a Computational Fluid Dynamics (CFD) model could be used to analyze

differences in gas flow between the NC and CCA during CPAP administration. Importantly, the

CCA is intended for use specifically during CPAP, and it produced nearly identical waveforms to

the NC in the CPAP trials. Therefore, the altered morphology of the CCA waveforms in the "no

mask" and "mask with no O_2" conditions has limited clinical impact, as these conditions are not

representative of typical CPAP usage.

However, the fact that CPAP consistently blunted the capnograms from both the NC and

CCA is more concerning. The $ETCO_2$ value and capnogram morphology are critical in

identifying causes of breathing difficulties and monitoring responses to therapy. For example,

the phase III alveolar plateau slope is an indirect marker of ventilation-perfusion (V/Q)

mismatch, and changes in the α- and β-angles of the capnogram can suggest bronchospasm,

airway obstruction, or rebreathing (21). During CPAP, these waveform features are altered or

diminished, limiting the utility of capnography in identifying these respiratory conditions.

Therefore, prehospital care providers must exercise caution when interpreting waveform

morphology during CPAP, as the typical diagnostic features may not be reliably visible. Future

research should investigate how waveform morphology changes under CPAP in both healthy

individuals and patients with respiratory conditions to better understand how capnography can

be used in this setting.

420 Capnography Sampler Effect on $ETCO_2$ and Respiration Rate

Overall, no differences were found between $ETCO_2$ and RR percent error when

measuring capnography via a traditional nasal-oral cannula (NC) or the novel CPAP-

Capnography Adapter (CCA). The observation that a leak between the face and mask was

present during CPAP in all NC trials and absent in all CCA trials indicates that the CCA met its

design objectives. While the NC did have a higher RR error than the CCA (9.423% vs. 0.690%),

this can be attributed to a single trial (Group 5 for the patient "Kenton Parkers") where an artifact

caused the LIFEPAK-15 to record a doubled respiration rate. This artifact was not noted in any

other trials, and its effect was not statistically significant. However, this error was present for all

20 breaths of the trial in question, so it should not be ignored; it is possible that something about

the NC or particular respiratory profile used for the trial predisposed the monitor to make the

error. Additional experiments would be needed to determine if the artifact is truly associated with

the use of the NC or if it originates from another source.

433 Mask Condition Effect on $ETCO_2$ and Respiration Rate

Administering CPAP significantly reduced the measured $ETCO_2$ (0.810) when compared

to "no mask" (0.983), which is consistent with the waveform observations. While a reduction in

$ETCO_2$ could indicate reduced $PaCO_2$, the fact that the HPS did not model $ETCO_2$ and instead

had a set target value indicates that the measured $ETCO_2$ did not accurately reflect the

mannequin's breathing profile during CPAP. Both capnography samplers recorded $ETCO_2$

values within five percent of the HPS's target $ETCO_2$ in the control "no mask" condition (NC:

1.4% higher; CCA: 4.89% lower), so their measurement of the partial pressure of CO_2 at the

HPS' nares was relatively accurate. Consequently, the notable decrease in $ETCO_2$ during CPAP

indicates that the CO_2 at the nares was diluted by the high oxygen flow rate (which can exceed

100 L/min) (45). Thus, the reduction in measured $ETCO_2$ is not an artifact of the capnography

samplers themselves. As a result, this $ETCO_2$ likely would no longer correlate with $PaCO_2$ in a

human subject. Further evidence that the functionality of the capnography samplers is not

compromised by CPAP is the fact that no differences in RR percent error were found between

the "no mask", "mask with no O_2", and "mask with CPAP" conditions—indicating that the

capnography samplers obtain sufficient gas samples to record measurements during all mask

conditions. Therefore, healthcare professionals should use $ETCO_2$ values obtained during

CPAP with caution, as a decreased $ETCO_2$ value might not indicate a true decrease in a

patient's $PaCO_2$.

Relationship with Previous Studies

In 2012, Razi et al. showed good correlation between $PaCO_2$ and $ETCO_2$ obtained

during mechanical ventilation (including CPAP) in a hospital setting. However, these patients

were intubated and monitored in a mainstream manner (46). In 2015, Piquilloud et al. used an

NC sampler to monitor capnography in ICU patients receiving non-invasive ventilation (NIV),

and found that $ETCO_2$ was inadequate to predict both $PaCO_2$ value and variations over time.

However, they only included 11 patients in their study, and used bi-level positive airway

pressure (BiPAP) instead of CPAP (47). A much larger study of 154 patients was published in

2021 by Uzunay et al. that showed a significant difference between $ETCO_2$ and $PaCO_2$ during

both non-invasive BiPAP and CPAP in the emergency department. However, a positive

moderate correlation was present, so the authors stated that capnography monitoring during

NIV may still be beneficial for predicting $PaCO_2$ changes in response to therapy—allowing for a

quicker decision to be made regarding switching to intubation (28). The mainstream

capnography monitoring method they used is not compatible with prehospital CPAP nor existing

EMS cardiac monitors, though. Most recently, Sakuraya et al. showed in 2022 that $PaCO_2$ and

$ETCO_2$ correlate well during CPAP when measured via an NC in a sidestream manner, and

correlate even better when measured in a mainstream manner. Their study was conducted on

60 recently extubated ICU patients. The authors concluded that the results of previous studies

monitoring $ETCO_2$ during NIV were mixed likely due to physiological issues and shortcomings of

exhalation sample collection (12).

None of the existing studies described changes to waveform morphology nor used a

prehospital CPAP system. Further, Sakuraya et al. is the only one that used a capnography

sampler compatible with common EMS cardiac monitors during non-invasive CPAP. All the

studies presented here assessed the correlation of $PaCO_2$ to $ETCO_2$ in human subjects, and

they achieved mixed results likely due to physiological factors and variations in methodology.

Our study complements this work by showing that—with physiological factors and variation

removed through the use of an HPS—$ETCO_2$ value and capnogram morphology are directly

compromised by CPAP itself. We could not assess $PaCO_2$ due to the limitations of the

mannequin used here; however, we show that the $ETCO_2$ value and capnogram shape should

not be interpreted with current protocols. Additional research into interpreting the value and

waveform when taken during CPAP is needed.

Limitations

The primary limitation of this study is that it was conducted using simulated patient

profiles on a Human Patient Simulator (HPS). The CAE Healthcare HPS is extremely accurate

at mixing respiratory gasses and mimicking human breathing, so it is commonly used in

anesthesia training (38,48–50). Using an HPS rather than human subjects allows for greater

control of confounding variables, facilitates rapid data collection, and relieves the ethical

concerns (and IRB approval) of testing a novel capnography sampler on patients in respiratory

distress who are receiving CPAP. However, it is not a perfect substitute for testing on human

subjects. For example, human patients exhibit significant differences in lung compliance, airway

dynamics, and facial anatomy, all of which can affect the seal of the CPAP mask and,

consequently, the measurement of CO_2. Mask leakage, in particular, may behave differently in

human patients than in the HPS, which could influence $ETCO_2$ measurements and waveform

morphology.

The HPS used in this study also has fixed physiological parameters, which limits its

ability to simulate real-time variability seen in human patients. In clinical settings, factors such

as emotions, stress, or pain can affect a patient's respiratory rate and CO2 production, adding

additional layers of complexity not captured by the simulator (51). Furthermore, while we believe

the waveform alterations and decreases in $ETCO_2$ seen during CPAP in the HPS trials are

consistent with what would be observed in human subjects, these results must be validated in

clinical settings with actual patients to confirm their generalizability. The high flow rate of CPAP,

which likely diluted exhaled CO_2 and blunted the waveforms in the simulator, is inherent to

CPAP therapy itself and would likely cause similar effects in human patients. However, human

trials are necessary to verify this assumption and account for patient-specific factors.

Another limitation of this study is related to capnography sampling. This study primarily

utilized nasal sampling with the CCA and oro-nasal sampling with the NC. In clinical practice,

patients undergoing CPAP often breathe through their mouths, particularly in cases of

respiratory distress, which could influence the capnography readings (32). The HPS does not

differentiate between nasal and oral breathing, which limits the ability to analyze how different

breathing patterns affect capnography measurements in humans. Future studies should

investigate whether nasal, oral, or combined sampling methods provide the most accurate

$ETCO_2$ readings during CPAP in clinical settings.

While our study demonstrated significant changes in capnography waveforms and

$ETCO_2$ during CPAP administration, this does not imply that capnography is an ineffective tool

for patients receiving CPAP. Capnography can still provide valuable insights into a patient's

ventilation status, but healthcare providers must be mindful of the limitations posed by high flow

rates and CO_2 dilution.

Conclusions

Our study developed a novel CPAP-compatible capnography adapter (CCA) to address

the issue of the nasal cannula (NC) disrupting the CPAP mask seal. Testing showed that both

the CCA and NC provided accurate respiration rate measurements, but CPAP administration

consistently reduced $ETCO_2$, likely due to CO_2 dilution from high flow rates. These findings

suggest that current capnography protocols may not reliably reflect ventilation during CPAP

therapy and that CPAP compromises capnogram morphology. Key next steps include

conducting controlled clinical trials to evaluate these changes in human patients, particularly in

prehospital and emergency care settings where capnography is widely used. These trials should

assess the reproducibility of our findings across different patient populations and clinical

conditions, such as COPD, asthma, and heart failure. Additionally, research should explore

modifications to capnography sampling methods and equipment, such as alternative sampling

locations or improved mask sealing, to mitigate CO_2 dilution. Mainstream capnography may also

warrant investigation as an alternative to sidestream methods commonly used in prehospital

settings. Further, developing algorithms or software that adjust capnography readings for

CPAP-related artifacts is another important avenue for future work. Machine learning models

could potentially detect and compensate for waveform blunting and CO_2 dilution, improving the

diagnostic utility of capnography during CPAP. Studies combining capnography data with other

physiological metrics, such as pulse oximetry, may provide more robust methods for assessing

ventilation.

Acknowledgments

The authors thank Steve Wilson for generously providing equipment that was vital for data

collection. This work was funded by the Abrams Scholarship from the UNC/NCSU Joint

Department of Biomedical Engineering, as well as significant in-kind support from the UNC

School of Nursing Simulation Center, UNC/NCSU Joint Department of Biomedical Engineering,

and Durham Technical Community College EMS Education program.

References

1. NEMSIS [Internet]. [cited 2022 Jun 14]. 911 Call Complaint vs. EMS Provider Findings Dashboard. Available from: https://nemsis.org/view-reports/public-reports/version-2-public-dashboards/v2-911-call-complaint-vs-ems-provider-findings-dashboard/
2. Burton JH, Harrah JD, Germann CA, Dillon DC. Does End-tidal Carbon Dioxide Monitoring Detect Respiratory Events Prior to Current Sedation Monitoring Practices? Acad Emerg Med. 2006;13(5):500–4.
3. Lightdale JR, Goldmann DA, Feldman HA, Newburg AR, DiNardo JA, Fox VL. Microstream Capnography Improves Patient Monitoring During Moderate Sedation: A Randomized, Controlled Trial. Pediatrics. 2006 Jun 1;117(6):e1170–8.
4. Arakawa H, Kaise M, Sumiyama K, Saito S, Suzuki T, Tajiri H. Does pulse oximetry accurately monitor a patient's ventilation during sedated endoscopy under oxygen supplementation? Singapore Med J. 2013 Apr;54(4):212–5.
5. Bickler PE, Feiner JR, Severinghaus JW. Effects of Skin Pigmentation on Pulse Oximeter Accuracy at Low Saturation. Anesthesiology. 2005 Apr 1;102(4):715–9.
6. Pulse Oximetry May Be Inaccurate in Patients with Darker Skin. AJN Am J Nurs. 2021 Apr;121(4):16.
7. Sjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. Racial Bias in Pulse Oximetry Measurement. N Engl J Med. 2020 Dec 17;383(25):2477–8.
8. Castro D, Patil SM, Keenaghan M. Arterial Blood Gas [Internet]. StatPearls [Internet]. StatPearls Publishing; 2021 [cited 2021 Nov 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536919/
9. Barten CW, Wang ESJ. Correlation of end-tidal CO2 measurements to arterial Paco2 in nonintubated patients. Ann Emerg Med. 1994 Mar 1;23(3):560–3.
10. Takano Y, Sakamoto O, Kiyofuji C, Ito K. A comparison of the end-tidal CO2 measured by portable capnometer and the arterial P CO2 in spontaneously breathing patients. Respir Med. 2003 May 1;97(5):476–81.
11. Corbo J, Bijur P, Lahn M, Gallagher EJ. Concordance Between Capnography and Arterial Blood Gas Measurements of Carbon Dioxide in Acute Asthma. Ann Emerg Med. 2005 Oct 1;46(4):323–7.
12. Sakuraya M, Douno E, Iwata W, Takaba A, Hadama K, Kawamura N, et al. Accuracy evaluation of mainstream and sidestream end-tidal carbon dioxide monitoring during noninvasive ventilation: a randomized crossover trial (MASCAT-NIV trial). J Intensive Care [Internet]. 2022 [cited 2023 Jun 13];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932153/
13. Hunter CL, Silvestri S, Dean M, Falk JL, Papa L. End-tidal carbon dioxide is associated with mortality and lactate in patients with suspected sepsis. Am J Emerg Med. 2013 Jan;31(1):64–71.
14. Hunter CL, Silvestri S, Ralls G, Stone A, Walker A, Mangalat N, et al. Comparing Quick Sequential Organ Failure Assessment Scores to End-tidal Carbon Dioxide as Mortality Predictors in Prehospital Patients with Suspected Sepsis. West J Emerg Med. 2018 May;19(3):446–51.
15. Caputo ND, Fraser RM, Paliga A, Matarlo J, Kanter M, Hosford K, et al. Nasal cannula end-tidal CO2 correlates with serum lactate levels and odds of operative intervention in penetrating trauma patients: a prospective cohort study. J Trauma Acute Care Surg. 2012 Nov;73(5):1202–7.
16. Donald MJ, Paterson B. End tidal carbon dioxide monitoring in prehospital and retrieval medicine: a review | Emergency Medicine Journal. Emerg Med J EMJ. 2006;23(9):728–30.

17. You B, Peslin R, Duvivier C, Dang Vu V, Grilliat JP. Expiratory capnography in asthma: Eur Respir J. 1994 Feb 1;7(2):318–23.

18. Chopin C, Fesard P, Mangalaboyi J, Lestavel P, Chambrin MC, Fourrier F, et al. Use of capnography in diagnosis of pulmonary embolism during acute respiratory failure of chronic obstructive pulmonary disease. Crit Care Med. 1990 Apr;18(4):353–7.

19. Hunter CL, Silvestri S, Ralls G, Papa L. Prehospital end-tidal carbon dioxide differentiates between cardiac and obstructive causes of dyspnoea. Emerg Med J EMJ. 2015 Jun;32(6):453–6.

20. Nik Hisamuddin NAR, Rashidi A, Chew KS, Kamaruddin J, Idzwan Z, Teo AH. Correlations between capnographic waveforms and peak flow meter measurement in emergency department management of asthma. Int J Emerg Med. 2009 Feb 24;2(2):83–9.

21. Kodali BS. Capnography Outside the Operating Rooms. Anesthesiology. 2013 Jan 1;118(1):192–201.

22. Cappiello JL, Hocker MB. Noninvasive Ventilation in Severe Acute Asthma. Respir Care. 2014 Oct 1;59(10):e149–52.

23. Pinto VL, Sharma S. Continuous Positive Airway Pressure [Internet]. StatPearls [Internet]. StatPearls Publishing; 2021 [cited 2021 Nov 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482178/

24. Schwerin DL, Goldstein S. EMS Prehospital CPAP Devices. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 Nov 23]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK470429/

25. Padilla ACH, Trampont T, Lafon T, Daix T, Cailloce D, Barraud O, et al. Is prehospital endobronchial intubation a risk factor for subsequent ventilator associated pneumonia? A retrospective analysis. PLOS ONE. 2019 May 23;14(5):e0217466.

26. Williams B, Boyle M, Robertson N, Giddings C. When Pressure is Positive: A Literature Review of the Prehospital Use of Continuous Positive Airway Pressure. Prehospital Disaster Med. 2013 Feb;28(1):52–60.

27. Gravenstein JS, Jaffe MB, Gravenstein N, Paulus DA, editors. Capnography [Internet]. 2nd ed. Cambridge: Cambridge University Press; 2011 [cited 2021 Nov 23]. Available from: https://www.cambridge.org/core/books/capnography/ACB43C8143D05B1E8011A39676E83 9BE

28. Uzunay H, Selvi F, Bedel C, Karakoyun OF. Comparison of ETCO2 Value and Blood Gas PCO2 Value of Patients Receiving Non-invasive Mechanical Ventilation Treatment in Emergency Department. SN Compr Clin Med. 2021 Aug 1;3(8):1717–21.

29. Stryker [Internet]. LIFEPAK 15 monitor/defibrillator - Operating Instructions. Available from: https://www.stryker.com/content/dam/stryker/ems/resources/operating-instructions/international/3314911-030_int-eng_lifepak_15_operating_instructions.pdf

30. Akcil EF, Dilmen OK, Tunali Y. Capnography as a Tool to Improve Noninvasive Ventilation: Technical Key Topics and Clinical Implications. In: Esquinas AM, editor. Noninvasive Mechanical Ventilation: Theory, Equipment, and Clinical Applications [Internet]. Cham: Springer International Publishing; 2016. p. 179–81. Available from: https://doi.org/10.1007/978-3-319-21653-9_19

31. Murphy G. How to Use EtCO2 During CPAP [Internet]. JEMS: EMS, Emergency Medical Services - Training, Paramedic, EMT News. 2021 [cited 2023 Mar 20]. Available from: https://www.jems.com/patient-care/how-to-use-etco2-during-cpap/

32. EMS1 [Internet]. [cited 2023 Mar 20]. Capnography and CPAP: Making the best better. Available from: https://www.ems1.com/ems-products/medical-equipment/airway-management/articles/capnography-and-cpap-making-the-best-better-D4VNbrgNjXgEndqN/

33. McLendon K, Edemekong PF. EMS Field Identification Of Chronic Obstructive Pulmonary Disease (COPD). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Jun 13]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK493230/

34. Orange County North Carolina [Internet]. 2020. Emergency Medical Services Medical
Practice Protocols. Available from: https://orangecountync.gov/DocumentCenter/View/4414
35. Formlabs [Internet]. 2016 [cited 2023 Mar 7]. General Purpose Resins: Material Properties
Data. Available from: https://formlabs-media.formlabs.com/datasheets/1801089-TDS-
ENUS-0P.pdf
36. Formlabs [Internet]. 2020 [cited 2023 Mar 7]. Material Data Sheet: Elastic 50A. Available
from: https://formlabs-media.formlabs.com/datasheets/2001420-TDS-ENUS-0.pdf
37. Formlabs [Internet]. 2023 [cited 2023 Mar 7]. FormCurePost-CureSettings.pdf. Available
from: https://support.formlabs.com/s/article/Form-Cure-Time-and-Temperature-
Settings?language=en_US
38. HPS Anesthesia Human Patient Simulator | CAE Healthcare [Internet]. [cited 2023 Mar 20].
Available from: https://www.caehealthcare.com/patient-simulation/hps/
39. Phillips JS, Pangilinan LP, Mangalindan ERE, Booze JL, Kallet RH. A Comparison of
Different Techniques for Interfacing Capnography With Adult and Pediatric Supplemental
Oxygen Masks. Respir Care. 2017 Jan 1;62(1):78–85.
40. Twisk JWR, editor. Multivariate Mixed Model Analysis. In: Applied Mixed Model Analysis: A
Practical Guide [Internet]. 2nd ed. Cambridge: Cambridge University Press; 2019 [cited
2023 Mar 20]. p. 151–65. (Practical Guides to Biostatistics and Epidemiology). Available
from: https://www.cambridge.org/core/books/applied-mixed-model-analysis/multivariate-
mixed-model-analysis/24F30835C3D1A00EA835A8AA9251F27D
41. Huang FL. MANOVA: A Procedure Whose Time Has Passed? Gift Child Q. 2020 Jan
1;64(1):56–60.
42. Tabachnick BG, Fidell LS, Ullman JB. Using multivariate statistics. Vol. 6. pearson Boston,
MA; 2013.
43. Formlabs [Internet]. [cited 2022 Nov 29]. Buy Clear Resin. Available from:
https://formlabs.com/store/clear-resin/
44. Quinn M, St Lucia K, Rizzo A. Anatomy, Anatomic Dead Space. In: StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Sep 17]. Available from:
http://www.ncbi.nlm.nih.gov/books/NBK442016/
45. Kempley S, Reeves J, Wilkins A. High oxygen flow rates with the UCL Ventura CPAP
device. Lancet Respir Med. 2021 Apr 1;9(4):e35.
46. Razi E, Moosavi GA, Omidi K, Khakpour Saebi A, Razi A. Correlation of End-Tidal Carbon
Dioxide with Arterial Carbon Dioxide in Mechanically Ventilated Patients. Arch Trauma Res.
2012;1(2):58–62.
47. Piquilloud L, Thevoz D, Jolliet P, Revelly JP. End-tidal carbon dioxide monitoring using a
naso-buccal sensor is not appropriate to monitor capnia during non-invasive ventilation. Ann
Intensive Care. 2015 Feb 12;5:2.
48. Antošová T, Rožánek M. Scenario of short anesthesia administration prepared for human
patient simulator. In: 2015 E-Health and Bioengineering Conference (EHB). 2015. p. 1–4.
49. Tripathy DK, Dhar M, Bhardwaj BB, Hemanthkumar K, Talawar P, Rao S. Use of a human
patient simulator for apnea studies: a preliminary in vitro trial. Korean J Anesthesiol. 2022
Jul 13;75(5):437–44.
50. Gaba D. Simulator training in anesthesia growing rapidly:CAE Model Born at Stanford. J
Clin Monit. 1996 Mar 1;12(2):195–8.
51. Nicolò A, Massaroni C, Schena E, Sacchetti M. The Importance of Respiratory Rate
Monitoring: From Healthcare to Sport and Exercise. Sensors. 2020 Nov 9;20(21):6396.

Supporting Information

[Figure S1]

Figure S1. Design iterations of the CPAP-Capnography Adapter (CCA). (A) The first prototype of the CCA, showing an area with excess cured resin obstructing the internal diameter of the nasal prong. (B) The first prototype attached to CapnoLine® tubing and a CPAP mask; the exit point of the CapnoLine® tubing is labeled. (C) The second prototype of the CCA, showing the internal guide tube added to prevent kinking. (D) The nasal sampler of the CCA printed with Formlabs Clear V4 resin, with damage visible on the right nasal prong. CCA = CPAP-capnography adapter.

[Figure S2]

Figure S2. Representative capnography waveforms across all experimental groups for patient "Stan D. Ardman II" (Healthy Male). Representative waveforms from all experimental groups are shown. The consistency of the waveforms within each trial is highlighted. Capnography samplers and mask conditions are labeled. NC = naso-oral cannula, CCA = CPAP-capnography adapter, O_2 = oxygen gas, CPAP = continuous positive airway pressure.

NC	CCA

No mask

Mask with no O2

Mask with CPAP

Elbow Adapter:

Nasal Sampler: